Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
The ASCRS Business of Refractive Cataract Surgery (BRiCS) Summit, which took place September 27–28 in Irving, Texas, brought together practice teams to emphasize the fact that for advanced-technology IOL adoption to be successful, all members of the practice need to be educated on various aspects.
With great opportunity in the world of IOLs also comes a challenge: how to discuss these options efficiently in a targeted manner without overwhelming or causing confusion for the patient. EyeWorld spoke with three members of its Cataract Editorial Board to learn how they manage this discussion.
➤ Topline Phase 3 results for sublingual, opioid-free sedation ➤ Phase 1 results for non-surgical cell therapy for corneal edema ➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients ➤ Update on Phase 3 study evaluating treatment for progressive myopia ➤ FDA to review NDA for first-in-class dry eye treatment ➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform ➤ ASCRS news and events
➤ FDA approves new ‘full range of vision’ IOL ➤ Imaging platform designed for patients in supine position receives FDA clearance ➤ Last patient dosed in Phase 3 study of non-IV, non-opioid sedation method ➤ Phase 2 study begins to assess neuropathic corneal pain treatment ➤ Plans to submit BLA for treatment of severe vision loss due to retinitis pigmentosa ➤ Research discovers protein related to AMD ➤ ASCRS news and events
➤ Last patient visit in proof-of-concept cell therapy ➤ Phase 2 data for allergic eye inflammation drop published ➤ NDA resubmission to the FDA for topical ocular reproxalap ➤ Positive topline results from Phase 2b suprachoroidal wet AMD therapy ➤ Complimentary access to video journal ➤ Partnership news ➤ ASCRS news and events
➤ Roll-out expanded for presbyopia-correcting IOL ➤ Study: Phase 3 clinical trials evaluate phentolamine ophthalmic solution ➤ AI listening innovation for ophthalmologists ➤ ASCRS news and events
The inaugural ASCRS Business of Refractive Cataract Surgery (BRiCS) Summit took place over the weekend, offering attendees the knowledge and tools they need to successfully and confidently offer advanced-technology IOLs in their practice.
A recent study explored the influence of angle kappa on multifocal IOL outcomes. Two of the researchers shared with EyeWorld the motivation behind this study, what was discovered, and what this means for future research.
The new ASCRS Business of Refractive Cataract Surgery Summit took place September 27–28 in Irving, Texas, with the goal of helping practices grow their use of and improve their implementation of advanced-technology IOLs.
The Cullen Eye Institute residents reviewed “Prediction of the small aperture intraocular lens on visual acuity in patients with keratoconus” from the Journal of Cataract & Refractive Surgery.